Showing results (21-30 of 31) with videos related to
Sort By:
Pageof 4
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 13, 2001
Application of rat hepatocyte culture to predict in vivo metabolic auto-induction: studies with DFP, a cyclooxygenase-2 inhibitorD A Nicoll-Griffith, J M Silva, N Chauret, et al.Science (New York, N.Y.)|January 29, 1982
Planetary radio astronomy observations from voyager 2 near saturnJ W Warwick, D R Evans, J H Romig, et al.Science (New York, N.Y.)|November 23, 1979
Planetary radio astronomy observations from voyager 2 near jupiterJ B Pearce, A C Riddle, J W Warwick, et al.Bioorganic & Medicinal Chemistry Letters|August 28, 1999
SAR in the alkoxy lactone series: the discovery of DFP, a potent and orally active COX-2 inhibitorY Leblanc, P Roy, S Boyce, et al.Journal of Medicinal Chemistry|April 10, 1999
2,3-Diarylcyclopentenones as orally active, highly selective cyclooxygenase-2 inhibitorsW C Black, C Brideau, C C Chan, et al.Science (New York, N.Y.)|July 4, 1986
Voyager 2 radio observations of uranusJ W Warwick, D R Evans, J H Romig, et al.Nature|March 5, 2002
Ultra-relativistic electrons in Jupiter's radiation beltsS J Bolton, M Janssen, R Thorne, et al.The Journal of Pharmacology and Experimental Therapeutics|July 20, 1999
Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profilesC C Chan, S Boyce, C Brideau, et al.Bioorganic & Medicinal Chemistry Letters|July 16, 1999
The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitorP Prasit, Z Wang, C Brideau, et al.Science (New York, N.Y.)|June 30, 1995
Outburst of Jupiter's synchrotron radiation after the impact of comet Shoemaker-Levy 9I de Pater, C Heiles, M Wong, et al.Pageof 4